Clostridium difficile associated infection, diarrhea and colitis.

@article{Hookman2009ClostridiumDA,
  title={Clostridium difficile associated infection, diarrhea and colitis.},
  author={P. Hookman and J. Barkin},
  journal={World journal of gastroenterology},
  year={2009},
  volume={15 13},
  pages={
          1554-80
        }
}
A new, hypervirulent strain of Clostridium difficile, called NAP1/BI/027, has been implicated in C. difficile outbreaks associated with increased morbidity and mortality since the early 2000s. The epidemic strain is resistant to fluoroquinolones in vitro, which was infrequent prior to 2001. The name of this strain reflects its characteristics, demonstrated by different typing methods: pulsed-field gel electrophoresis (NAP1), restriction endonuclease analysis (BI) and polymerase chain reaction… Expand
Clostridium difficile: epidemiology, pathogenesis, management, and prevention of a recalcitrant healthcare-associated pathogen.
Clostridium difficile is the leading cause of healthcare-associated infectious diarrhea. Although C difficile is part of normal flora in some healthy individuals, patients with selective risk factorsExpand
Toxigenic Clostridium difficile Infection in Children: Performance of Toxin A/B Immunoassay
Introduction Clostridium difficile is an anaerobic, spore-forming, Grampositive bacillus that infects the large intestine or colon (1). It is an important nosocomial bacterium causing a range ofExpand
Clostridium difficile: a problem of concern in developed countries and still a mystery in Latin America.
TLDR
This review attempts to summarize reports of C. difficile infection worldwide, especially in Latin America, and aims to provide an introduction to the problems associated with this pathogen for those countries that might face outbreaks of epidemic strains of the bacterium for the first time in the near future. Expand
Clostridium difficile infection: clinical spectrum and approach to management
  • C. Vaishnavi
  • Medicine
  • Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology
  • 2011
TLDR
Adjunctive measures used for CDAD are probiotics and prebiotics, fecotherapy, adsorbents and immunoglobulin therapy, among the new therapies fidaxomicin has recently been approved by the American Food and Drugs Administration for treatment of CDAD. Expand
Clostridium difficile infection: review
TLDR
The goal of this review is to update physicians on current scientific knowledge of C. difficile infection, focusing also on fecal microbiota transplantation which is a promising therapy. Expand
Clinical approach to severe Clostridium difficile infection: update for the hospital practitioner.
TLDR
Early surgical consultation is necessary in patients who do not respond to medical therapy or who demonstrate rising white blood cell counts or hemodynamic instability indicative of fulminant colitis, and it has been demonstrated that vancomycin is the more effective antibiotic in cases of severe disease. Expand
Clinical spectrum & pathogenesis of Clostridium difficile associated diseases.
  • C. Vaishnavi
  • Medicine
  • The Indian journal of medical research
  • 2010
TLDR
Clostridium difficile associated disease (CDAD) is a serious condition with mortality up to 25 per cent in frail elderly people andVancomycin is the drug of choice for severely ill patient, whereas metronidazole can be used for mild to moderately ill patients. Expand
Established and potential risk factors for Clostridum difficile infection.
  • C. Vaishnavi
  • Medicine
  • Indian journal of medical microbiology
  • 2009
TLDR
The established and potential risk factors of CDAD, along with the epidemiology, diagnostic modalities, management and preventive measures of the disease have been elaborated. Expand
Advances in the treatment of Clostridium difficile with fidaxomicin: a narrow spectrum antibiotic
TLDR
Fidaxomicin is a novel, narrow spectrum antibiotic with potent bactericidal activity against C. difficile and low activity against the normal gut microbiota and has been shown to be noninferior in initial clinical response to CDAD compared to vancomycin. Expand
Assessment of severity of Clostridium difficile infection.
  • Subrata Ghosh
  • Medicine
  • Canadian journal of gastroenterology = Journal canadien de gastroenterologie
  • 2011
TLDR
Clinicians need to be able to assess the severity of CDI early in the course of the disease to tailor medical management or anticipate surgery, and vancomycin should be considered first-line therapy in patients with moderate to severe CDI. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 180 REFERENCES
Review: Clostridium difficile-Associated Disorders/Diarrhea and Clostridium difficile Colitis: The Emergence of a More Virulent Era
TLDR
The authors’ conclusions were that a previously uncommon strain of C. difficile with vari- with increased production of toxins A and B was found. Expand
Emergence of Clostridium difficile-associated disease in North America and Europe.
  • E. Kuijper, B. Coignard, P. Tüll
  • Biology, Medicine
  • Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
  • 2006
TLDR
The clinical spectrum of Clostridium difficile-associated disease (CDAD) ranges from diarrhoea to severe life-threatening pseudomembranous colitis, and is recognised increasingly in a variety of animal species and in individuals previously not considered to be predisposed. Expand
Emergence and Control of Fluoroquinolone-Resistant, Toxin A–Negative, Toxin B–Positive Clostridium difficile
TLDR
C. difficile–associated disease in this institution decreased to fewer than 5 cases per 1,000 admissions during a 6-month period, and it was found that careful attention to improvement of infection control interventions was the most important means of controlling this nosocomial pathogen. Expand
Clostridium difficile: changing epidemiology and new treatment options
TLDR
The early recognition of Clostridrium difficile-associated diarrhoea caused by NAP1/027 is necessary to start rapid treatment, to prevent complications, and to prevent further spread of the bacterium. Expand
Narrative Review: The New Epidemic of Clostridium difficileAssociated Enteric Disease
TLDR
Clostridium difficile is the most common identifiable bacterial cause of diarrhea in the United States and the most sensitive diagnostic test, but the enzyme immunoassay is now used by most laboratories because of ease of processing, cost, and speed of results. Expand
A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality.
TLDR
A strain of C. difficile that was resistant to fluoroquinolones and had binary toxin and a partial deletion of the tcdC gene was responsible for this outbreak ofC.difficile-associated diarrhea. Expand
The challenges posed by reemerging Clostridium difficile infection.
  • D. Blossom, L. McDonald
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2007
TLDR
Challenges posed by the changing epidemiology of CDAD are compounded by current limitations in diagnostic testing, treatment, and infection control. Expand
Antibiotic-Associated Diarrhea: Candidate Organisms other than Clostridium Difficile
TLDR
K. pneumoniae, Candida species, and Staphylococcus aureus were found to be potential causative organisms in C. Difficile negative AAD patients. Expand
Clostridium difficile--associated diarrhea.
TLDR
Preventive measures include the judicious use of antibiotics, thorough hand washing between patient contacts, use of precautions when handling an infected patient or items in the patient's immediate environment, proper disinfection of objects, education of staff members, and isolation of the patient. Expand
Clinical and Epidemiological Aspects of Clostridium difficile
TLDR
The changing epidemiology of CDAD across North America and internationally is discussed, as well as the common diagnostic methods and molecular typing tools for this pathogen. Expand
...
1
2
3
4
5
...